Imunon Inc - Asset Resilience Ratio
Imunon Inc (IMNN) has an Asset Resilience Ratio of 0.00% as of December 2024. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check how strategically is Imunon Inc's equity deployed to assess the company's strategic physical and investment asset allocation.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2004–2024)
This chart shows how Imunon Inc's Asset Resilience Ratio has changed over time. See Imunon Inc balance sheet quality to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down Imunon Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see IMNN stock market capitalisation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $0.00 | 0% |
| Total Liquid Assets | $0.00 | 0.00% |
Asset Resilience Insights
- Limited Liquidity: Imunon Inc maintains only 0.00% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company maintains a balanced mix of cash and short-term investments.
Imunon Inc Industry Peers by Asset Resilience Ratio
Compare Imunon Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
Cyclacel Pharmaceuticals Inc
NASDAQ:CYCC |
Biotechnology | -55.36% |
|
Krystal Biotech Inc
NASDAQ:KRYS |
Biotechnology | 23.06% |
|
Verona Pharma PLC ADR
NASDAQ:VRNA |
Biotechnology | 0.00% |
|
Centessa Pharmaceuticals PLC ADR
NASDAQ:CNTA |
Biotechnology | 33.37% |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161 |
Biotechnology | 8.08% |
|
Hebei Changshan Biochem Pharma
SHE:300255 |
Biotechnology | -0.03% |
|
BB Biotech AG
SW:BION |
Biotechnology | 0.05% |
Annual Asset Resilience Ratio for Imunon Inc (2004–2024)
The table below shows the annual Asset Resilience Ratio data for Imunon Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 0.00% | $0.00 | $9.72 Million | -- |
| 2023-12-31 | 44.97% | $9.86 Million | $21.92 Million | -3.36pp |
| 2022-12-31 | 48.33% | $21.25 Million | $43.98 Million | +8.08pp |
| 2021-12-31 | 40.25% | $29.80 Million | $74.05 Million | -- |
| 2020-12-31 | 0.00% | $0.00 | $37.53 Million | -- |
| 2019-12-31 | 20.86% | $7.99 Million | $38.28 Million | -9.57pp |
| 2018-12-31 | 30.43% | $14.26 Million | $46.86 Million | +3.65pp |
| 2017-12-31 | 26.78% | $12.72 Million | $47.51 Million | +21.33pp |
| 2016-12-31 | 5.45% | $1.68 Million | $30.85 Million | -16.58pp |
| 2015-12-31 | 22.03% | $10.80 Million | $49.03 Million | -14.22pp |
| 2014-12-31 | 36.24% | $24.17 Million | $66.69 Million | -45.11pp |
| 2013-12-31 | 81.36% | $37.16 Million | $45.67 Million | +49.66pp |
| 2012-12-31 | 31.70% | $8.04 Million | $25.36 Million | +0.59pp |
| 2011-12-31 | 31.11% | $10.16 Million | $32.65 Million | +15.45pp |
| 2010-12-31 | 15.66% | $395.56K | $2.53 Million | -22.80pp |
| 2009-12-31 | 38.47% | $5.70 Million | $14.81 Million | +21.32pp |
| 2008-12-31 | 17.15% | $4.06 Million | $23.69 Million | +9.46pp |
| 2007-12-31 | 7.68% | $3.00 Million | $39.04 Million | -34.58pp |
| 2006-12-31 | 42.26% | $8.00 Million | $18.93 Million | +4.55pp |
| 2005-12-31 | 37.71% | $6.00 Million | $15.91 Million | -20.33pp |
| 2004-12-31 | 58.04% | $9.90 Million | $17.05 Million | -- |
About Imunon Inc
Imunon, Inc., a clinical-stage biotechnology company, focuses on developing immunotherapies and vaccines in the United States. The company's lead clinical program is IMNN-001, a DNA-based immunotherapy that is in a Phase 3 clinical trial for the localized treatment of advanced ovarian cancer, as well as in the IND-enabling phase for colorectal and pancreatic cancers, and in the discovery phase fo… Read more